NEW YORK -- Johnson & Johnson is leveraging its technologies used in the development of vaccines for Ebola, Zika, and HIV in a race to stop the spread of COVID-19, the illness caused by the new coronavirus.
Interview
Johnson & Johnson tests 10 variants of coronavirus vaccine
Group eyes human trials in fall, utilizing Ebola and HIV knowledge
Johnson & Johnson's Dutch unit Janssen Vaccines & Prevention started development of a vaccine for the new coronavirus in January as soon as the genetic code became available. © Reuters
Read Next
Latest on Interview
